News

FDA Grants De Novo Designation for Vela Diagnostics’ Next Generation Sequencing HIV-1 Genotyping Assay

Vela Diagnostics’ Sentosa® SQ HIV-1 Genotyping Assay is the first FDA De Novo designated Next Generation Sequencing (NGS) assay for detecting HIV-1 drug resistance mutations (DRMs). November 06, 2019 08:00 AM Eastern Standard Time FAIRFIELD, N.J.–(BUSINESS WIRE)–Vela Diagnostics announced today that it has received FDA authorization to market its in vitro diagnostic test for the detection of HIV-1 genomic…

Read More

Curetis Group Company Ares Genetics Launches AI-powered Molecular Antibiotic Susceptibility Test

Vienna, Austria, and Holzgerlingen, Germany, October 28, 2019, 08:00 am CET – Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that its fully-owned subsidiary Ares Genetics has launched an early access program for its novel, artificial intelligence (AI) powered, next-generation sequencing (NGS) based molecular…

Read More

OpGen Announces Stock Offering

GAITHERSBURG, Md., Oct. 23, 2019 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq:OPGN) today announced the pricing of an underwritten offering of an aggregate of 4,700,000 units at an effective price of $2.00 per unit. Each unit is comprised of one share of common stock (or common stock equivalent) and one common warrant to purchase one share…

Read More

OpGen / Curetis Obtain U.S. Patent Covering Acuitas Lighthouse® Software

GAITHERSBURG, Md., Oct. 23, 2019 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN) announced today that the United States Patent and Trademark Office (the “USPTO”) has allowed a key OpGen patent covering the Lighthouse Profiling technology used in the company’s software for tracking antimicrobial resistant pathogens. Patent application US 20160085912A1 “Systems, Apparatus, and Methods for Generating…

Read More

Curetis Group Subsidiary Ares Genetics Signs R&D and Option Agreement with Leading Global IVD Corporation

Holzgerlingen, Germany, and Vienna, Austria, September 16, 2019, 08:00 am CET – Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that its wholly-owned subsidiary Ares Genetics GmbH (“Ares Genetics”), Vienna, Austria, has entered into a multi-phase partnership with an undisclosed leading global in vitro…

Read More

Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses

Gaithersburg, MD, USA, Amsterdam, the Netherlands, and Holzgerlingen, Germany, 04 September 2019, 0800 am CET, 0655 am ET  – OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, and Curetis N.V. (Euronext: CURE, “Curetis”), a developer of next-level molecular diagnostic solutions, today…

Read More

Curetis Files for U.S. FDA 510(k) Clearance of Unyvero Lower Respiratory Tract (LRT) Infection Assay for Bronchoalveolar Lavage (BAL) Specimens

Curetis Files for U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens Final LRT BAL panel demonstrates overall weighted average sensitivity of up to 94.7% and overall weighted average specificity of up to 98.4% Unyvero provides results after approximately five hours, compared to an average of several days for standard-of-care methods Amsterdam, the Netherlands,…

Read More

Epigenomics AG Receives MedTech Outlook’s 2019 Top 10 In-Vitro Diagnostics Award

BERLIN and SAN DIEGO, (GLOBE NEWSWIRE) — Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) announced today that it was selected by MedTech Outlook to receive the 2019 Top 10 In-Vitro Diagnostics Award. Conducted annually, the award recognizes companies that are excelling in their respective fields. The selection panel noted that through its unique, proprietary DNA methylation…

Read More

New Clinical Data Support the Utility of Epi proColon Blood Test for Colorectal Cancer (CRC) Screening in Patients with Lynch Syndrome (LS), the Most Common Hereditary CRC Syndrome

Berlin (Germany), June 17, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology, today reported new study results suggesting that Epi proColon, a colorectal cancer screening test approved for patients who are unwilling or unable to be…

Read More

New Data on Curetis Unyvero LRT Panel for Pneumonia to be Presented at ASM Microbe 2019

Amsterdam, the Netherlands, San Diego, CA, USA, and Holzgerlingen, Germany, June 04, 2019 – Curetis N.V. (the “Company” and, together with Curetis GmbH and Curetis USA Inc. “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that new data on its Unyvero System and LRT Application Cartridge for pneumonia will be presented at the…

Read More